Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 [Yahoo! Finance]
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]